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Introduction
Nigeria has the third largest number of people living with 
human immunodeficiency virus (HIV) in the world.1 The 
HIV prevalence among women attending antenatal clinics 
(ANC) was 4.6% in 2008, with 5-6 million births recorded 
annually.2 A Nigerian child’s greatest risk of infection with 
HIV is through mother-to-child-transmission (MTCT). In sub-
Saharan Africa, in the absence of any prevention, between 
16.5-26.4% of children who are born to HIV-positive 
mothers will be infected during the peripartum period.3 In 
2007, 220 000 children were estimated to be HIV-positive 
in Nigeria.4 
The provision of antiretroviral (ARV) prophylaxis remains 
the most efficacious strategy to prevent MTCT. Compared 
to placebo, ARVs in sub-Sahara Africa reduces the in-
utero and intrapartum risk of MTCT by 50%.5 However, 
the evidence of the effectiveness of ARV prophylaxis is 
based on data from experimental and closely monitored 
population studies6-8 which report outcomes based on 
analyses isolated from the realities of whole healthcare 
systems.9The benefits of PMTCT become more modest 
when the constraints of the healthcare systems in resource-
poor countries are taken into account. The gap between 
the number of HIV-positive pregnant women who need 
prophylaxis in developing countries, and those who receive 
it, is wide. Nigeria is one of the countries with a large number 
of pregnant women living with HIV. It had only 11% PMTCT 
coverage in 2008. Nigeria alone contributes to 30% of the 
global gap in PMTCT coverage.10 It is insufficient for ARV 
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prophylactic regimens to be simply efficacious. They also 
have to be embedded in the routines of healthcare services. 
Healthcare systems must make them available, services 
must be organised so that efficiency and effectiveness are 
optimised, and people in need must be willing and able to 
use the services.11 
This paper reports on the evaluation of a service 
improvement process that the Global HIV/AIDS Initiative 
Nigeria (GHAIN) supported to enhance the performance of 
PMTCT in the Nigerian healthcare system. Generally, the 
service improvement interventions are underutilised in the 
public sector of resource-poor settings as an approach to 
embedding effective treatments. Where they have been 
used, generally they have been limited to single sites,11-12 
or small population groups,13 the analysis has not included 
measurable outcomes,14 or the research was managed 
within the context of a community trial.15 
Background
GHAIN initially supported PMTCT services in 26 sites in 
2005, and expanded to 157 sites across all 36 states and the 
federal capital territory by June 2008. Most of the sites are 
secondary level hospitals and primary healthcare centres. A 
typical PMTCT site has an ANC with maternity services and 
access to a laboratory and pharmacy. GHAIN’s technical 
assistance includes six-day training, followed by monthly 
supervision, to ensure adherence to the Nigerian national 
guidelines and mentoring on clinical, logistical monitoring 
and evaluation. Client registration is open at any stage of 
pregnancy, although women are encouraged to book early. 
All pregnant women receive group education on ANCs, HIV 
in pregnancy, and PMTCT. One-on-one pre-test counselling 
precedes all HIV testing. Initially, most ANCs did not use 
the rapid HIV test kits. Samples of blood were sent to the 
laboratory and the client was given an appointment and 
asked to return to get the HIV test results. Those clients who 
tested positive were offered ARV prophylaxis, and could 
choose from five drug regimens that were recommended 
by the Nigerian PMTCT national guideline.16 These were 
azidothymidine (AZT) only; AZT/lamivudine (3TC)/single-
dose nevirapine (sdNVP); AZT/sdNVP; sdNVP and a triple 
regimen. The sdNVP regimen was recommended only for 
non-booked mothers in the labour ward. The HIV-positive 
women were assessed for antiretroviral therapy (ART) 
eligibility and referred to the ART clinic as appropriate. 
The review of monthly routine data identified three problems, 
namely low attendance at ANCs, the need to sustain the 
uptake of HIV counselling and testing (HCT) while scaling 
up PMTCT services, and a low proportion of HIV-positive 
women receiving ARV prophylaxis. The GHAIN-supported 
service improvement process began with a cause-and-effect 
analysis to describe the nature of the problem, explore the 
factors involved, identify the possible causes of each factor, 
and generate an analysis based on a fishbone diagram 
(Figure 1).  The analysis was conducted in conjunction with 
11 service providers and nine programme managers. 
Providers
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Figure 1: Fishbone diagram shows root causes of low uptake of antiretroviral drugs prophylaxis
Original Research: Closing the prevention of mother-to-child transmission gap in Nigeria
98 Vol 55 No 1S Afr Fam Pract 2013
The identified main root causes were grouped in four 
categories: 
•	 Service	provision-level	causes: The inability to provide 
HIV test results on the same day, poor quality of 
counselling due to a high workload, and staff attrition 
and turnover. 
•	 Patient-level	causes: A low rate of return after HIV testing 
to commence ARV prophylaxis because of distance, 
cost and domestic violence. This led to poor adherence 
to the timing of ARV prophylaxis administration. The 
facility deliveries were also low. 
•	 Resource-level	causes: Lack of cluster of differentiation 
4 testing in some facilities, insufficient funding to track 
defaulting HIV-positive women and occasional stock 
shortages of ARV drugs.
•	 Policy-level	 cause:	 Providers insisted on the triple or 
dual prophylaxis regimens. SdNVP was perceived to 
be an inferior option and was seldom provided, even 
though it was sometimes the only option in practice and 
part of the guidelines. 
The service improvement teams established in healthcare 
facilities acted on the three problems that were identified 
during the review of monthly routine monitoring data, 
namely low attendance at ANCs, sustaining the uptake of 
HCT and a low proportion of HIV-positive pregnant women 
receiving ARV prophylaxis. 
Firstly, meetings were held with religious and community 
leaders to advocate ANC service utilisation and the fight 
against stigma. Secondly, rapid HIV test kits were introduced 
in all ANCs. This enabled the healthcare provider to provide 
group pre-test HIV counselling with an opt-out option, 
individual post-test counselling, and test results on the same 
day. Thirdly, the frequency of support supervision increased, 
during which providers received feedback on service output 
and were encouraged to minimise missed opportunities for 
ARV prophylaxis. Providers were encouraged to offer AZT/
sdNVP or AZT/3TC/sdNVP as the regime of first choice, 
but to consider all regimens, including the sdNVP which 
was perceived to be inferior and rarely prescribed by 
doctors. In instances in which it was not feasible to provide 
combination ARV regimens, women were counselled on the 
use of sdNVP in labour and provided with a 200 mg tablet 
of sdNVP as a minimum therapy.17
In addition, providers were encouraged to check HIV-
positive women for eligibility for ART and to refer them 
to the ART clinic as appropriate. A new patient-tracking 
system using diaries was introduced in ANCs to optimise 
adherence. HIV-positive pregnant women on prophylaxis 
were given a return date which was recorded in the diary. 
At the end of every clinic day, a list of defaulters was drawn 
up and patients were tracked by telephone and home visits. 
The supervisors included the pharmacy in their visiting 
schedule. An early warning system for drug stock shortages 
was implemented. There was monthly monitoring of the 
maximum and minimum levels of ARV and HIV rapid test 
kits at each facility. 
Method
The service improvement interventions were evaluated as 
an indivisible whole, rather than according to individual 
components, by measuring changes in aggregated ANC 
routine service data between a six-month period prior to the 
service improvement process (July-December 2007) and six 
months after (January-June 2008). 
Each site provided monthly reports of aggregated service 
utilisation. Four output measures were applied to the 
cascade of PMTCT, from ANC attendance through to 
completion of ARV prophylaxis: 
•	 Number of women attending the ANC for the first time. 
•	 Number of pregnant women tested for HIV.
•	 Number of HIV-positive pregnant women receiving ARV 
prophylaxis. 
•	 Number of HIV-positive women newly initiated on ART.
In addition, a service ratio was used as a proxy indicator 
of the relative uptake of ARV prophylaxis. Ideally, the 
relative uptake of ARV prophylaxis would be measured 
as a proportion of the HIV-positive women giving birth (in 
a month) who had received ARV prophylaxis. However, 
the monthly service statistics did not allow for a direct 
correlation of individual delivery and ARV prophylaxis data. 
The service ratio calculates the number of women who 
received ARV prophylaxis in a month, over the number of 
women who tested positive for HIV in the same month. The 
working assumption was that a service ratio approaching 
or slightly exceeding one would indicate that the number of 
women receiving ARV prophylaxis was nearing the upper 
limit of known HIV- positive women within the programme. 
Data analysis
Data on attendance at ANCs, HCT, and ARV prophylaxis 
for six months pre- and six months post-intervention 
were exported from the national district health information 
system into Stata® 10.0 for analysis. Descriptive methods 
were used to characterise the monthly changes in the four 
output measures. Differences between the pre- and post-
intervention periods were tested with a bivariate Poisson 
regression model using the Stata® “xt” command to adjust 
the standard errors to account for clustering by ANCs. 
A p-value < 0.05 was the desired level of significance. The 
service ratio could not be calculated for 10% (71) of the 
monthly returns. Typically, this occurred when there were 
no HIV-positive pregnant women and no women receiving 
HIV prophylaxis (n = 60), or where there were no HIV-
positive women and a small number of women receiving 
HIV prophylaxis (n = 11). 
In these cases, the ratio was either undefined (0/0) or infinity 
(n/0, for all n > 0), and was excluded from the analysis. 
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A histogram of the service ratio showed it to be skewed with 
a heavy right tail. A natural log transformation was applied, 
producing more normally distributed data suitable for 
analysis with multiple linear regressions. These data were 
back-transformed in the presentation of the results. Each 
regression analysis involved one of the measures and the 
service improvement period was entered as a dichotomous, 
predictor variable. To determine the reduction in the number 
of MTCT events, it was necessary to link HIV-positive 
mothers to the child’s confirmed HIV status. This was not 
possible with the aggregated routine data. Crude estimates 
were calculated based on the known number of HIV-positive 
pregnant women in the programme. An estimate was 
made of the risk of MTCT and the risk reduction in MTCT 
by different ARV prophylaxis regimens. The estimates of 
the risk of MTCT without ARV prophylaxis in sub-Saharan 
Africa are broad-ranging from 21%,5 through 25%,3 and 
up to 40%.3 This risk is spread in three distinct periods, 
namely the in utero period (risk = 0.222), the intrapartum 
period of labour (risk = 0.444), and the postpartum period of 
breastfeeding (risk = 0.333).3
To estimate MTCT events that were averted during the in 
utero and intrapartum period by ARV prophylaxis taken 
by the pregnant women, adherence to the regimen was 
assumed. 
The number of averted MTCT events was calculated as 
the difference between transmission among HIV-positive 
pregnant women, which would have occurred without 
ARV prophylaxis [estimated with a lower range of 14% 
(0.666 x 21%) and higher range of 27% (0.666 x 40%) 
HIV transmission risk for in utero and intrapartum results 
combined],18 and the estimated number of MTCT events in 
the same group of pregnant women. 
The risk reduction effect of the reported ARV prophylaxis 
was applied using the following estimates per regimen:
•	 AZT reduces MTCT risk by 50%.19
•	 AZT/3TC regimen reduces MTCT risk by 63%.20
•	 sdNVP reduces MTCT risk by 48%.21
Results
By June 2008, the GHAIN project was supporting 196 PMTCT 
sites. Of these, 133 became a part of the programmatic 
support after the service improvement process that started 
in January 2008. Sixty-three sites had data going back six 
months prior to the service improvement interventions. 
Three sites had incomplete data. This evaluation included 
the 60 sites with complete pre- and post-intervention 
data only.
First-time attendance at antenatal clinics
A total of 120 537 first-time ANC attendees were recorded 
at the 60 clinics. There was substantial variation in the 
number of ANC attendees by facility. Some facilities 
reported monthly averages of more than 900 first-time ANC 
attendees, while others had fewer than 10 (mean = 167.4, 
median = 114.3).  Figure 2 shows the variation in monthly 
attendance across the 60 sites. Forty-eight per cent 
(58 276) and 52% (62 261) of total attendance occurred in 
the pre- and post-intervention periods, respectively. The 
post-intervention period had an increase in attendance of 
11.1 women per facility per month (p-value < 0.01).
Human immunodeficiency virus testing
A total of 104 851 HIV tests were conducted at the ANC 
clinics, 48 590 (47%) and 55 631 (53%) pre- and post- 
intervention respectively. The uptake of testing among first-
time ANC attendees increased post-intervention from 85% 
to 89%, with substantial variation by facility. Some facilities 
tested just under 900 clients per month, while others tested 
fewer than 10 (mean = 145.6). The pre-intervention period 
had on average 136.7 HIV tests per facility per month. This 
rose significantly to 154.5 post-intervention (p-value < 0.01). 
Over the 12-month period, an average of 449 pregnant 
women tested HIV-positive monthly. The average number of 
indentified HIV-positive women rose post-intervention from 
an average of 424 to 475 per month. 
Antiretroviral drugs prophylaxis
Figure 3 shows the changes in the uptake of ARV prophylaxis 
by drug regimen during the observation period. The monthly 
number of women receiving ARV prophylaxis increased 
from 198 pre-intervention to 325 post-intervention. In the 
pre-intervention period, an average of 3.3 women per 
facility per month received ARV prophylaxis. This rose to 
an average of 5.4 women per facility per month (p-value 
< 0.01). This represents a monthly average across the 60 
facilities of 198.3 women who received ARV prophylaxis in 
the pre-intervention period, rising to 325 women in the post-
intervention period. The relative use of sdNVP increased 
from an average of 17% pre-intervention to 36% post-
intervention. The AZT/sdNVP was the most commonly used 
regime pre-intervention (58%) and post-intervention (40%). 


























5 8 4 0 12 5 4 5 3 4 8 4
Aug-07 Sep-07 Oct-07 Nov-07 Dec-07 Jan-08 Feb-08 Mar-08 Apr-08 May-08 Jun-08
Average Maximum Minimum
Pre QAQI Post QAQI
QAQI: quality assurance, quality improvement
Figure 2: Number of first antenatal visits per month by facility
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who received AZT/3TC/sdNVP and the triple regimen from 
20% to 17%, and 5% to 7%, respectively. 
When sdNVP was excluded, there was still a significant rise 
in the delivery of ARV prophylaxis from a monthly facility 
average of 2.8 women in the pre-intervention period to 3.5 
women in the post-intervention period (p-value < 0.01). This 
represents a monthly average across the 60 facilities of 164.2 
women who received prophylaxis in the pre-intervention 
period. This rose to 207.6 women post-intervention. Over 
the 12-month period, 194 of the 5 389 HIV-positive pregnant 
women received the triple ARV prophylactic regimen in all 
60 facilities. This number increased significantly from 60 
pre-intervention to 134 post-intervention (p-value < 0.01). 
Thirty-six of the 60 facilities included in the study had an 
ART clinic. Of these, 29 facilities had a complete dataset 
on the number of HIV-positive pregnant women who 
started ART over the 12-month observation period. This 
number increased from 240 HIV-positive pregnant women 
who started ART pre-intervention to 348 post-intervention. 
It translated to an increase from an average of 1.4 HIV-
positive pregnant women who were started on ART per 
facility per month pre- intervention to two post-intervention 
(p-value < 0.01).
The service ratio: relative uptake of antiretroviral drugs 
prophylaxis
Figure 4 shows the changes in service ratio during the 
observation period. In the pre-intervention period, the 
service ratio averaged 0.47 per facility per month. In other 
words, on average, each facility provided ARV prophylaxis 
to 4.7 women for every 10 women who tested positive for 
HIV in the same month. In the post-intervention period, this 
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MTCT events without ARV drugs n Low High n Low High
14% 27% 14% 27%
MTCT without ARV drugs total HIV-positive women NA 2 541 355.7 686.1 2 848 398.7 769
MTCT without ARV drugs HIV-positive women on PMTC NA 1 188 166.3 320.8 1 951 273.1 526.8
MTCT events with ARV drugs
AZT/3TC/sdNVP 0.63 241 12.5 24.1 333 17.2 33.3
AZT/sdNVP 0.50 684 47.9 92.3 779 54.5 105.2
sdNVP 0.48 203 14.8 28.5 705 51.3 99
Triple regime 0.63 60 3.1 6.0 134 6.9 13.4
Total MTCT events with ARV drugs among HIV-positive 
women on PMTCT
1 188 78.3 150.9 1 951 130 250.8
MTCT events averted (D = B - C) among HIV-positive 
women on PMTCT
88.1 169.8 143.1 276
* MTCT event: (n) x (1-risk reduction) x (low/high estimate risk of mother-to-child transmission occurrence)
ARV: antiretroviral; AZT/3TC/sdNVP: azidothymidine/lamivudine/single-dose nevirapine; AZT/sdNVP: azidothymidine/single-dose nevirapine; HIV: human immunodeficiency virus; MTCT: mother-
to-child transmission; NA: not applicable because no antiretroviral drugs prophylaxis provided; PMTC: prevention of mother-to-child transmission; QAQI: quality assurance, quality improvement, 
sdNVP : single-dose nevirapine
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Estimates of averted mother-to-child transmission 
events 
A total of 2 541 and 2 848 pregnant women tested positive 
for HIV pre- and post-intervention, respectively. Table I 
shows estimates of MTCT events in the study population 
over the observation period. Considering a risk estimate 
of HIV MTCT in utero and intrapartum combined, ranging 
from 14-27% without ARV prophylaxis, the estimated 
number of MTCT events during these exposure periods 
among the HIV-positive pregnant women would have 
been between 355-686 pre-intervention, rising to between 
398-768 post-intervention. ARV prophylaxis was provided to 
1 188 and 1 951 HIV-positive pregnant women pre- and post-
intervention respectively. In the absence of prophylaxis, the 
estimated number of MTCT events in utero and intrapartum 
combined would have ranged from 166-320, rising to 
273-526 post-intervention. When the risk reduction effect 
of the ARV prophylaxis regimens was applied (no woman 
received the AZT-only regime), the estimated number of 
MTCT events decreased to a range between 78-150 pre-
intervention and between 130-250 post-intervention. 
Therefore, the estimated numbers of averted MTCT events 
ranged between 88-169 pre-intervention, and between 
143-276 post-intervention. 
Discussion 
This study showed that it is possible to undertake valuable 
implementation research with routine data, the potential of 
which is largely unexploited, thereby missing opportunities 
to enhance the increased utilistation of evidence-based 
interventions. Good routine data provide an opportunity to 
consider how best ARV prophylaxis can be delivered, and 
whether a service improvement intervention process can be 
used as a means of embedding effective treatments within 
a healthcare system. Service improvement intervention 
introduces changes in service organisations. This study 
showed a greater uptake of services accordingly. There was 
no significant difference between facilities excluded from 
the study and those included in terms of the communities 
served, service configuration and historical service output. 
However, the evidence presented in this paper was limited 
by the lack of randomisation and unavailability of a control 
group. Furthermore, the assumptions used to estimate 
averted MTCT events were drawn from control trials that 
had near perfect compliance,9 which is not always the case 
in routine service settings. Therefore, our findings tended to 
overestimate averted MTCT events. 
The paper used the service improvement intervention 
approach for the analysis of the problems and the 
development of solutions. Many European studies have 
assessed improvement in hospital outputs for specific 
disease management and the system’s response to quality 
improvement.22-27 However, these studies did not use routine 
data, hence their ability to better analyse associations 
between individual components of improvement strategies 
and output. These studies suggest that the patient safety 
system, changes in service organisation monitored by 
performance indicators, clinical guidelines and external 
assessments were associated with improvement in service 
output. The service improvement intervention presented 
in this paper included all these components, except the 
patient safety system.
The increase in ANC attendance post-intervention was 
encouraging. The factors that influenced poor attendance 
at ANCs and other services in Nigeria included education, 
finance, culture and quality of services.28-30 Our study’s service 
improvement intervention strategy combined service-
related interventions, patient tracking and sensitisation of 
community leaders. No other systematic changes in the 
political, socio-economical or general service organisation 
environment occurred during the observation period. There 
is evidence elsewhere that the introduction of PMTCT 
services in ANC settings, by improving the counselling skills 
of staff, had a positive impact on ANC utilisation.31 However, 
only 35% of pregnant women are likely to complete an 
ANC programme and have a skilled attendant at delivery 
in Nigeria.9,32 The retention of clients in the ANC system is 
challenging in Nigeria. When women fail to return for their 
ANC follow-up appointment, the completion of non-sdNVP 
prophylaxis regimes is compromised. 
This study suggests that an estimated 96 additional MTCT 
events were averted by improved uptake of ARV prophylaxis. 
Although AZT/3TC/sdNVP and AZT/sdNVP regimes have a 
greater HIV transmission risk reduction effect, the uptake 
of these regimens, which require adherence to multiple 
doses of treatment, was modest, despite being favoured by 
providers. However, the number of HIV-positive pregnant 
women on sdNVP trebled. In resource-constrained settings 
such as Nigeria, where barriers to access and factors that 
affect adherence to ARVs remain prevalent, sdNVP is still 
a valuable option.21,33 The sdNVP dose was dispensed 
at ANCs. The study did not establish if all women used 
the sdNV at the onset of labour. This problem was often 
found when evaluating similar PMTCT programmes in sub-
Saharan Africa,34 but there has been evidence of good 
adherence to sdNVP in resource-limited settings.35 Good 
counselling is important to ensure adherence.36 Using the 
good uptake of HIV testing (87%) as a proxy indicator for the 
quality of counselling, this study assumed good adherence. 
Improvements in service uptake extended beyond the ARV 
prophylaxis. The number of women who started on the triple 
ARV regimen also doubled, from 60 to 134, after the service 
improvement intervention. The programme should cater for 
the possibility of an increase in nevirapine resistance among 
women and infants who received sdNVP37,38 by training and 
sensitising healthcare providers about treatment options 
for nevirapine-exposed women. In Nigeria, improving the 
quality of services should be a key intervention in closing 
the PMTCT gap.
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Conclusion
This study, using routine service statistics, suggests that 
there are significant missed opportunities for PMTCT 
in existing programmes. Closing the PMTCT gap in 
Nigeria should start by optimising service uptake in 
existing programmes before starting new PMTCT sites. 
Simple changes in service organisation, coupled with 
strengthened support supervision and greater sensitisation 
of the community significantly improved the uptake of ARV 
prophylaxis in this study.
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